Matthew Herper at Forbes argues that the biotech boom of the past two years has been spurred by new drug launches and research breakthroughs. However, he cautions that some investors are currently "seeing rainbows and missing the rain."
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: weighting scheme increases GWAS power, and more.
Marc Tessier-Lavigne is to be the next president of Stanford University.
Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.
Journals and research funding agencies pledge to enable the sharing of Zika virus research.